Nearly half of cancer deaths due to smoking-attributable cancers
the ONA take:
Researchers from the American Cancer Society updated estimates of cancer-related deaths from smoking. The new numbers indicate an estimated 48.5% of the nearly 346,000 deaths from 12 cancers among adults 35 years and older were attributable to cigarette smoking.
The researchers used data from the 2011 National Health Interview Survey, the Cancer Prevention Study III, and the pooled contemporary cohort.
The results show that of an estimated 345,962 deaths, 167,805 were attributable to smoking cigarettes. Cancers of the lung, bronchus, and trachea and cancer of the larynx made up the largest proportion of smoking-attributable deaths: 80.2% and 76.6%, respectively.
In addition, approximately half of deaths from cancers of the oral cavity, esophagus, and urinary bladder were attributable to smoking.
The authors conclude that further progress in reducing cancer mortality will depend on more comprehensive tobacco control, including targeted cessation support.
An estimated 48.5% of the nearly 346,000 deaths from 12 cancers among adults 35 years and older were attributable to cigarette smoking.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|